Intermittent Fasting and Cancer: What the Research Says

Quick Answer: Early research suggests intermittent fasting may reduce cancer risk through multiple mechanisms — lower insulin, reduced inflammation, and enhanced cellular repair. Fasting during chemotherapy is an emerging area with promising early results but requires oncologist supervision. No fasting protocol should replace conventional cancer treatment.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Cancer treatment decisions must be made in consultation with a qualified oncologist. Do not alter your treatment plan or diet based on this article alone.

What We Know (and Don't Know) About Fasting and Cancer

Cancer research is complex, and fasting research is relatively young. What we have is a growing body of preclinical evidence (cell and animal studies), some observational data in humans, and a small number of clinical trials.

The honest summary: the mechanistic case for fasting reducing cancer risk is strong. The clinical evidence in humans is still developing. This distinction matters enormously when translating research into personal decisions.

Biological Mechanisms: Why Fasting May Matter for Cancer

Several biological pathways connect fasting to cancer biology:

Insulin and IGF-1 reduction Elevated insulin and insulin-like growth factor 1 (IGF-1) are associated with increased risk for multiple cancers, including breast, colon, and prostate cancer. Fasting dramatically lowers both. Research published in Cell Metabolism showed that fasting reduced IGF-1 by 40–60% in humans who fasted for five days (Brandhorst et al., 2015). Lower IGF-1 means less signaling through pathways that promote cell proliferation.

Autophagy Autophagy — the cellular "self-cleaning" process activated by fasting — allows the body to break down damaged and dysfunctional cells, including potentially pre-cancerous ones. The Nobel Prize in Physiology or Medicine was awarded in 2016 to Yoshinori Ohsumi for discoveries related to autophagy. While autophagy's role in cancer is dual-edged (it may suppress tumor initiation but also support survival in established tumors), its activation is generally considered protective in healthy cells.

Inflammation reduction Chronic inflammation is a well-established driver of cancer development. Fasting reduces markers of systemic inflammation, including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). You can read more about how fasting affects metabolism and inflammatory signaling.

Blood glucose stabilization Cancer cells preferentially consume glucose — a concept known as the Warburg effect. By reducing blood glucose and insulin, fasting theoretically reduces the fuel available to rapidly dividing cells. This is an active area of research, and the degree to which dietary glucose restriction affects human tumors remains under study.

Fasting and Cancer Prevention: What the Evidence Shows

Several large observational studies have linked caloric restriction and lower body weight to reduced cancer incidence. Since obesity is a known risk factor for at least 13 types of cancer (including breast, colon, endometrial, and kidney cancers), any intervention that reduces body fat and insulin resistance may reduce cancer risk indirectly.

A 2019 study in JAMA Internal Medicine found that women who fasted fewer than 13 hours per night had a 36% higher risk of breast cancer recurrence compared to those who fasted 13 or more hours (Marinac et al., 2016). This was an observational study, but the effect size is notable.

Mechanistic animal studies have consistently shown that caloric restriction extends lifespan and reduces tumor incidence in rodent models. Whether these results translate to humans remains uncertain — human cancer biology is far more complex.

Fasting During Chemotherapy: An Emerging Field

This is perhaps the most clinically relevant — and most controversial — area of fasting and cancer research.

The concept is called differential stress resistance (DSR). The idea: fasting may make normal healthy cells more resistant to the toxic effects of chemotherapy, while cancer cells (which are biologically compelled to keep growing) cannot enter a protected low-energy state. In theory, this could reduce chemo side effects while potentially making cancer cells more vulnerable.

A pilot clinical trial published in BMC Cancer (de Braud et al., 2016) found that short-term fasting around chemotherapy was safe and associated with reduced side effects in a small group of patients. Larger studies are ongoing.

Crucially, this work was pioneered by Dr. Valter Longo at USC, and his research group has shown effects in multiple cancer types. However, fasting during chemotherapy is not a standard of care and should only be attempted under direct oncologist supervision. Some cancers and some chemotherapy regimens may not be appropriate candidates.

Who Should Be Cautious

Fasting is not appropriate for everyone with cancer:

• Anyone currently underweight or with poor nutritional status — cancer-related malnutrition is a serious concern; fasting can worsen it
• People with cachexia (cancer-related muscle wasting) should not fast
• Those on certain medications where food timing matters
• People undergoing active treatment who have not discussed fasting with their oncologist

For cancer survivors in remission who are otherwise healthy, intermittent fasting may be appropriate as part of a broader metabolic health strategy — but again, only with physician involvement.

What About Specific Cancer Types?

Research is uneven across cancer types:

• Breast cancer: The most studied. Observational data is encouraging. Fasting appears to reduce estrogen and insulin, both relevant to hormone-receptor-positive breast cancer.
• Colorectal cancer: Strong mechanistic links through insulin resistance and inflammation. Less direct clinical data.
• Prostate cancer: Elevated IGF-1 is a known risk factor; fasting lowers IGF-1. No major clinical trials yet.
• Brain tumors (glioblastoma): Some case reports and small trials combining ketogenic diet with fasting. Highly experimental.

Practical Recommendations

For cancer prevention:

• A consistent 16:8 fasting window combined with a whole-food diet and regular exercise is a reasonable metabolic health strategy
• Prioritize weight management — adipose tissue is metabolically active and pro-inflammatory
• Support insulin sensitivity through fasting and diet (see our guide on insulin and fasting)
• Avoid ultra-processed foods and excess sugar during your eating window

For cancer survivors:

• Discuss any fasting protocol with your oncology team before starting
• Start conservatively — 12–14 hours overnight is a reasonable entry point
• Focus on nutritional density during your eating window; do not use fasting as a justification for caloric restriction if you're underweight or recovering

For those in active treatment:

• Do not fast without direct oncologist approval
• If your oncologist is open to exploring fasting around chemotherapy, ask about clinical trial options

Frequently Asked Questions

Does intermittent fasting cure cancer? No. There is no evidence that fasting cures cancer. It may reduce certain risk factors and, in conjunction with treatment, may have supportive effects — but it is not a cancer treatment. Anyone claiming fasting cures cancer is making an unsupported claim.

Can fasting feed cancer cells? This concern is sometimes raised, but there is no evidence that short-term fasting "feeds" cancer cells. The Warburg effect describes cancer cells' preferential use of glucose, but fasting reduces blood glucose — the opposite of what this concern implies. During fasting, the body shifts to ketone production, which cancer cells are generally less able to use than normal cells.

Is fasting safe during radiation therapy? There is very limited research on fasting during radiation. Some preclinical data suggests potential benefit, but this has not been established in human trials. Speak with your radiation oncologist before making any dietary changes during treatment.

How long should I fast for potential cancer-protective effects? Based on current evidence, even modest overnight fasting of 13+ hours appears to have measurable effects (per the Marinac breast cancer study). For deeper metabolic effects like autophagy induction and IGF-1 reduction, longer fasts appear more potent — but these must be balanced against other health considerations. A beginners guide can help you start conservatively.

Citations

1. Brandhorst S, et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. Cell Metab. 2015;22(1):86–99.
2. Marinac CR, et al. Prolonged nightly fasting and breast cancer prognosis. JAMA Oncol. 2016;2(8):1049–1055.
3. de Braud F, et al. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016;16:360.
4. Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab. 2014;19(2):181–192.
5. Nencioni A, et al. Fasting and cancer: molecular mechanisms and clinical application. Nat Rev Cancer. 2018;18(11):707–719.